[{"begin": 0, "end": 190, "text": "Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F", "tokenized_text": "Cheah CY , Chihara D , Horowitz S , Sevin A , Oki Y , Zhou S , Fowler NH , Romaguera JE , Turturro F , Hagemeister FB , Fayad LE , Wang M , Neelapu SS , Nastoupil LJ , Westin JR , Rodriguez MA , Samaniego F", "type": "authors", "id": 0}, {"begin": 190, "end": 223, "text": ", Anderlini P, Nieto Y, Fanale MA", "tokenized_text": ", Anderlini P , Nieto Y , Fanale MA", "type": "authors", "id": 1}, {"begin": 225, "end": 358, "text": "Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes", "tokenized_text": "Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes", "type": "title", "id": 2}, {"begin": 360, "end": 369, "text": "Ann Oncol", "tokenized_text": "Ann Oncol", "type": "venue", "id": 3}, {"begin": 371, "end": 375, "text": "2016", "tokenized_text": "2016", "type": "year", "id": 4}]